[1]
|
中华医学会儿科学分会临床药理学组, 《中华儿科杂志》编辑委员会. 中国儿科超说明书用药专家共识[J]. 中华儿科杂志, 2016, 54: 101-103. doi: 10.3760/cma.j.issn.0578-1310.2016.02.007 |
[2]
|
中华人民共和国中央人民政府. 中华人民共和国医师法[EB/OL]. (2021-08-20)[2022-09-13]. http://www.npc.gov.cn/npc/c30834/202108/d954d9fa0af7458aa862182dc50a0d63.shtml. |
[3]
|
Zuo W, Sun Y, Liu R, et al. Management guideline for the off-label use of medicine in China (2021)[J]. Expert Rev Clin Pharmacol, 2022, 11: 1-16. |
[4]
|
Reay T, Berta WB, Kohn MK. What's the evidence on evidencebased management?[J]. Acad Manag Perspect, 2009, 23: 5-18. doi: 10.5465/AMP.2009.45590137 |
[5]
|
Oxford Centre for Evidence-based Medicine. Oxford centre for evidence-based medicine: levels of evidence[EB/OL]. (2009-03)[2022-09-13]. https://www.cebm.ox.ac.uk/resources/levels-of-evidence/oxford-centre-for-evidence-based-medicine-levels-ofevidence-march-2009. |
[6]
|
广东省药学会. 超药品说明书用药药物经济学评价专家共识[J]. 今日药学, 2016, 26: 681-683. https://www.cnki.com.cn/Article/CJFDTOTAL-YAXU201610001.htm |
[7]
|
Gazarian M, Kelly M, McPhee JR, et al. Off-label use of medicines: consensus recommendations for evaluating appropriateness[J]. Med J Aust, 2006, 185: 544-548. doi: 10.5694/j.1326-5377.2006.tb00689.x |
[8]
|
Gazarian M, Kelly M, McPhee JR, et al. Off-label use of medicines: consensus recommendations for evaluating appropriateness[J]. Med J Aust, 2006, 185: 544-548. doi: 10.5694/j.1326-5377.2006.tb00689.x |
[9]
|
National Institute for Health and Care Excellence. Evidence Summaries: Unlicensed and Off-Label Medicines-Integrated Process Statement[Internet][R]. London: National Institute for Health and Care Excellence (NICE), 2013: Process and Methods Guides No. 14. |
[10]
|
European Commission Enterprise And Industry Directorate-General. A guideline on summary of product characteristics (SmPC)[EB/OL]. (2013-01-21)[2022-09-13]. https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/product-information/how-prepare-review-summary-product-characteristics. |
[11]
|
Dooms M, Killick J. Off-label use of medicines: The need for good practice guidelines[J]. Int J Risk Saf Med, 2017, 29: 17-23. doi: 10.3233/JRS-170737 |
[12]
|
中华人民共和国中央人民政府. 中华人民共和国民法典[EB/OL]. (2020-06-02)[2022-09-13]. https://epaper.gmw.cn/gmrb/html/2020-06/02/nw.D110000gmrb_20200602_7-01.htm. |
[13]
|
Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations[J]. BMJ, 2004, 328: 1490. doi: 10.1136/bmj.328.7454.1490 |
[14]
|
Oxford Centre for Evidence-Based Medicine. Explanation of the 2011 OCEBM levels of evidence[EB/OL]. (2021-12-23)[2022-09-13]. https://www.cebm.ox.ac.uk/resour-ces/levels-of-evidence/explanation-of-the-2011-ocebm-levels-of-evidence. |
[15]
|
Herrero Fernandez M, Molina Villaverde R, Arroyo Yustos M, et al. The Off-Label Use of Antineoplastics in Oncology Is Limited But Has Notable Scientific Support in a University Hospital Setting[J]. Front Pharmacol, 2019, 10: 1210. doi: 10.3389/fphar.2019.01210 |
[16]
|
Yang J, Lin W, Chen Y. Off-label use of tamoxifen in a Chinese tertiary care hospital[J]. Int J Clin Pharm, 2019, 41: 555-562. doi: 10.1007/s11096-019-00788-5 |
[17]
|
中华人民共和国卫生部. 药品不良反应报告和监测管理办法[EB/OL]. (2011-05-24)[2022-09-13]. http://www.gov.cn/flfg/2011-05/24/content_1870110.htm. |
[18]
|
Cook RJ. Off-label drug use as a consent and health regulation issue in New Zealand[J]. J Bioeth Inq, 2015, 12: 251-258. doi: 10.1007/s11673-014-9568-6 |
[19]
|
Lenk C, Duttge G. Ethical and legal framework and regulation for off-label use: European perspective[J]. Ther Clin Risk Manag, 2014, 10: 537-546. |
[20]
|
Czaja AS, Ross ME, Liu W, et al. Electronic health record (EHR) based postmarketing surveillance of adverse events associated with pediatric off-label medication use: A case study of short-acting beta-2 agonists and arrhythmias[J]. Pharmacoepidemiol Drug Saf, 2018, 27: 815-822. doi: 10.1002/pds.4562 |
[21]
|
王丹. 药品不良反应主动监测及其发展趋势[J]. 中国药物警戒, 2015, 12: 600-602, 610. doi: 10.19803/j.1672-8629.2015.10.007 |
[22]
|
Coughlin M, Goldie CL, Tregunno D, et al. Enhancing metabolic monitoring for children and adolescents using second-generation antipsychotics[J]. Int J Ment Health Nurs, 2018, 27: 1188-1198. doi: 10.1111/inm.12417 |
[23]
|
Emmerich J, Dumarcet N, Lorence A. France's new framework for regulating off-label drug use[J]. N Engl J Med, 2012, 367: 1279-1281. doi: 10.1056/NEJMp1208347 |
[24]
|
医疗机构药事管理规定. 中华人民共和国中央人民政府[EB/OL]. (2011-03-30)[2022-09-13]. http://www.gov.cn/zwgk/2011-03/30/content_1834424.htm. |
[25]
|
Vargas-Rivas JE, Sabater-Hernández D, Calleja-Hernández MA, et al. Role of the hospital pharmacy and therapeutics committee in detecting and regulating off-label drug use[J]. Int J Clin Pharm, 2011, 33: 719-721; author reply 722-723. doi: 10.1007/s11096-011-9532-z |
[26]
|
Zheng Z, Zeng Y, Huang H. Pharmacists' role in off-label drug use in China[J]. Eur J Hosp Pharm, 2018, 25: 116. |
[27]
|
Skledar SJ, Corman SL, Smitherman T. Addressing innova-tive off-label medication use at an academic medical center[J]. Am J Health Syst Pharm, 2015, 72: 469-477. |
[28]
|
Loblova O, Csanadi M, Ozieranski P, et al. Patterns of alternative access: Unpacking the Slovak extraordinary drug reimbursement regime 2012-2016[J]. Health Policy, 2019, 123: 713-720. doi: 10.1016/j.healthpol.2019.05.021 |
[29]
|
Teagarden JR, Dreitlein WB, Kourlas H, et al. Influence of pharmacy benefit practices on off-label dispensing of drugs in the United States[J]. Clin Pharmacol Ther, 2012, 91: 943-945. doi: 10.1038/clpt.2011.367 |
[30]
|
Todd AE. No need for more regulation payors and their role in balancing the cost and safety considerations of off-label prescriptions[J]. Am J Law Med, 2011, 37: 422-443. doi: 10.1177/009885881103700209 |
[31]
|
American Society of Clinical Oncology. Reimbursement for cancer treatment: coverage of off-label drug indications[J]. J Clin Oncol, 2006, 24: 3206-3208. doi: 10.1200/JCO.2006.06.8940 |
[32]
|
国家市场监督管理总局. 药品注册管理办法[EB/OL]. (2020-07-01)[2022-09-22]. https://baike.baidu.com/item/%E8%8D%AF%E5%93%81%E6%B3%A8%E5%86%8C%E7%AE%A1%E7%90%86%E5%8A%9E%E6%B3%95/2566520?fr=aladdin. |